CLINICAL RESEARCH OF INFECTIONS IN TRANSPLANTATION

移植感染的临床研究

• 批准号: 6226761
• 负责人: CARLOS V PAYA
• 金额: $ 7.09万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2005-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6226761
• 关键词: Betaherpesvirinae; Epstein Barr virus; clinical research; homologous transplantation; human subject; medical complication; opportunistic infections

DESCRIPTION: (Adapted from Applicant s Abstract) One major barrier limiting the success of human allotransplantation is the transplantation related infec- tious complications. While significant progress has been made in the last decade in elucidating the pathogenesis and the optimal management of trans- plant infectious complications, a number of infections continue to cause sig- nificant morbidity and mortality in the transplant recipient. The applicant is an active clinical investigator in this field and has identified two major areas in which additional research is required to overcome the impact of these infections. These include addressing the role of the family of beta-herpes viruses (CMV, HHV-6, and HHV-7) and Epstein Barr Virus (EBV) induced post- transplant lymphoproliferative disease (PTLD). This clinical research is a fertile ground for training of future clinician investigators as it conveys multidisciplinary interaction: immunology, diagnostic virology, and transplan- tation medicine. Through this award, the applicant is seeking the support to obtain additional training in specific aspects of clinical research including formal courses in patient-oriented research, interactions with the clinical research unit (GCRC), GMP facilities, and additional training in immunotherapy of chronic viral infections in transplant patients. The applicant is seeking the support to, within a clinical research group, address the two mentioned focused areas in infectious diseases in transplantation and in which future clinician investigators will be formally trained. The specific aims that this application will pursue include: I) Study the clinical relevance of HHV-6 and HHV-7 in organ transplant recipients and their interaction with other opportu- nistic viral infections (CMV, EBV, HBV, and HCV). II) Define the clinical value of EBV viral load for the prevention and management of EBV-PTLD, and test the feasibility of cell-based immune therapy for the prevention and trea- tment of EBVPTLD in EBV naive solid organ transplant recipients. Altogether, this award will allow us to address, through rigorous patient-oriented re- search, two areas of transplant infectious complications, which are limiting success in human transplantation. Moreover, it will facilitate to train a cadre of future clinician investigators who will further advance this impor- tant field of clinical medicine.

描述：（改编自申请人的摘要）一个主要的障碍限制 人类同种异体移植的成功是与移植相关的感染， 复杂的情况。虽然在过去几年中取得了重大进展， 十年来，在阐明发病机制和最佳管理的跨- 植物感染并发症，一些感染继续造成信号， 在移植受者中显著的发病率和死亡率。申请人 一个活跃的临床研究者在这一领域，并确定了两个主要的 需要进一步研究以克服这些影响的领域 感染.这些措施包括解决家庭的作用β-疱疹 病毒（CMV，HHV-6和HHV-7）和爱泼斯坦巴尔病毒（EBV）诱导的后 移植淋巴组织增生性疾病（PTLD）。这项临床研究是一项 培养未来临床研究人员的沃土，因为它传达了 多学科的相互作用：免疫学，诊断病毒学，和transplan- 癫痫药 通过这个奖项，申请人正在寻求支持， 获得临床研究特定方面的额外培训，包括 以患者为导向的研究的正式课程，与临床 研究单位（GCRC）、GMP设施和免疫治疗的额外培训 移植病人的慢性病毒感染申请人寻求 支持，在临床研究小组内，解决上述两个问题 移植中传染病的重点领域， 临床研究者将接受正式培训。具体目标是， 申请将追求包括：I）研究HHV-6的临床相关性， 器官移植受者中HHV-7及其与其他机会的相互作用 病毒感染（CMV、EBV、HBV和HCV）。 （二）临床定义 EBV病毒载量对预防和管理EBV-PTLD的价值，以及 测试基于细胞的免疫治疗用于预防和治疗的可行性， EBVPTLD在EBV初治实体器官移植受者中的治疗总的来说， 这一奖项将使我们能够通过严格的以病人为导向的改革， 搜索，移植感染并发症的两个领域，这是限制 人类移植的成功。此外，这将有助于培养一个 未来的临床研究人员将进一步推动这一重要的， 临床医学的新领域。